Henry Schein (NASDAQ:HSIC) Stock Price Expected to Rise, UBS Group Analyst Says

Henry Schein (NASDAQ:HSIC) had its price objective hoisted by stock analysts at UBS Group from $94.00 to $95.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. UBS Group‘s price target suggests a potential upside of 7.66% from the stock’s previous close.

Other research analysts also recently issued reports about the company. Piper Sandler boosted their price objective on Henry Schein from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Barclays reiterated an “overweight” rating and issued a $100.00 target price (up from $86.00) on shares of Henry Schein in a report on Thursday, August 6th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. Weiss Ratings raised Henry Schein from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, August 21st. Finally, Citigroup restated a “buy” rating and set a $112.00 price target (up from $100.00) on shares of Henry Schein in a report on Wednesday, August 5th. Nine research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $93.33.

Henry Schein Trading Up 7.0%

NASDAQ HSIC traded up $5.74 during mid-day trading on Wednesday, reaching $88.24. 3,904,638 shares of the stock were exchanged, compared to its average volume of 1,351,026. The stock has a market cap of $9.83 billion, a P/E ratio of 25.73, a P/E/G ratio of 1.56 and a beta of 0.87. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.32 and a quick ratio of 0.73. Henry Schein has a one year low of $68.70 and a one year high of $92.18. The stock has a 50 day simple moving average of $86.35 and a 200-day simple moving average of $81.18.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.20. The business had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.48 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The business’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.38 earnings per share. On average, analysts anticipate that Henry Schein will post 5.36 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Southpoint Capital Advisors LP boosted its holdings in Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after acquiring an additional 700,000 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Henry Schein by 2.0% during the first quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock valued at $211,734,000 after acquiring an additional 56,687 shares in the last quarter. M.D. Sass LLC increased its holdings in shares of Henry Schein by 2.9% during the first quarter. M.D. Sass LLC now owns 1,273,316 shares of the company’s stock valued at $93,843,000 after acquiring an additional 35,443 shares in the last quarter. Bank of America Corp DE raised its position in shares of Henry Schein by 5.9% during the first quarter. Bank of America Corp DE now owns 1,221,585 shares of the company’s stock worth $90,031,000 after purchasing an additional 68,593 shares during the period. Finally, Defilade Capital Management L.P. raised its position in shares of Henry Schein by 94.8% during the first quarter. Defilade Capital Management L.P. now owns 624,037 shares of the company’s stock worth $45,992,000 after purchasing an additional 303,615 shares during the period. 96.62% of the stock is owned by institutional investors and hedge funds.

More Henry Schein News

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Henry Schein reported Q3 EPS of $1.56, above the roughly $1.34–$1.36 analyst estimates cited in reports and up from $1.38 a year earlier. The company also raised its FY2026 EPS guidance, supporting the earnings outlook. Henry Schein Q3 results and guidance
• Positive Sentiment: Sales grew 4.0% year over year to about $3.47 billion, with recent analysis pointing to volume-driven dental gains and margin initiatives as operating supports. Q3 business and margin analysis
• Neutral Sentiment: Revenue was nearly in line with expectations, rather than a clear top-line beat. A tariff refund also contributed to the quarter, so investors may assess how much of the performance can be sustained through ongoing operations. Q3 revenue results
• Negative Sentiment: Delays in discretionary dental procedures are weighing on demand and tempering the otherwise strong earnings report, a risk that may limit confidence in near-term growth. Discretionary dental delays

About Henry Schein

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.